UNSPSC 51111730: Azotomycin

This classification denotes an antineoplastic antibiotic with the molecular formula C17H23N7O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6TQY580E8M, chemically known as l-norleucine, 6-diazo-n-(6-diazo-n-l-gamma-glutamyl-5-oxo-l-norleucyl)-5-oxo- but generally known as azotomycin, which bears US NIH Compound Identifier 24281. Azotomycin most often comes in base and sodium forms. The term AZOTOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5).

UNSPSC 51111730 Azotomycin, a Commodity code, shows limited recent state and local procurement activity directly aligned with the code's nominal scope. The two most recent opportunities posted under this code involve pharmaceutical products — one a piggyback contract for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) through a cooperative purchasing vehicle, and the other a county-level procurement for Naloxone and drug deactivation systems — neither of which represents azotomycin specifically. State and local health departments and counties are the primary issuing bodies visible in recent activity, using cooperative purchasing arrangements and competitive bidding processes to acquire pharmaceutical supplies for emergency preparedness and public health support.

The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract to Chartwell Rx LLC on August 28, 2026, valued at $2,999,999.11 over the life of the contract, through the MMCAP Infuse cooperative purchasing vehicle; this was a completed award, not an open solicitation. Seminole County, Florida released an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with a response deadline of July 26, 2023, requiring quarterly deliveries and including vendor responsibility for shipping costs. Recent activity centers on Florida and Illinois, though the code's mapping appears to diverge from actual procurement needs — state and local buyers are acquiring broad-spectrum antibiotics and emergency-response pharmaceuticals rather than azotomycin-specific products, suggesting the code may be misclassified for these opportunities or sees limited genuine demand under its nominal scope.